Synapse
⌘+K
Synapse
PulseExploreClubsResearchersJournals
Instagram
HomeClubsExplore
December 8, 2025BloodOpen Access

Thrombopoietin receptor agonists combined with intensive immunosuppressive therapy improve outcomes in elderly patients with severe aplastic anemia: A single-center retrospective study

View Full Paper
Ask AI
Bookmark
Share

Authors

BSBo ShaoQCQin CaoHJHao Jiang

Discussion

Loading...

Member takes

Overview

Retrospective analysis shows intensified immunosuppressive therapy with Hetrombopag improves clinical outcomes in elderly patients with severe aplastic anemia, indicating better remission rates.

Key Points

  • To evaluate the impact of combining thrombopoietin receptor agonists with intensive immunosuppressive therapy in elderly patients with severe aplastic anemia.
  • Single-center retrospective analysis of 32 patients aged ≥ 60 with severe aplastic anemia
  • Patients received either IST plus Hetrombopag or IST alone
  • Follow-up duration was median 540 days, with comparison of treatment responses and outcomes
  • Cumulative response rates at 12 months were 92.9% for IST+HPAG and 85.7% for IST alone
  • Complete remission rates improved to 35.7% for IST+HPAG and 33.3% for IST alone
  • Univariate analysis indicated higher Charlson Comorbidity Index scores correlated with poorer treatment response

Cite This Study

Shao et al. (2025) studied this question.

synapsesocial.com/papers/69362f364fa91c937236d322https://doi.org/10.1182/blood-2025-1119
View Full Paper
Ask AI
Bookmark
Share